Tretinoin Real-World Response Rate: What Percentage of Users Actually See Results?

What Percentage of Tretinoin Users See Results for Fine Wrinkles?

The percentages here come from controlled studies of specific tretinoin formulations and skin conditions, not from a response rate for all tretinoin users. The most detailed per-patient breakdown comes from controlled trials of Renova 0.02% cream, approved as an adjunct, alongside a comprehensive skin care and sunlight avoidance program, for mitigation of fine facial wrinkles [1]. Five vehicle-controlled 24-week trials enrolled 324 evaluable tretinoin patients and 332 vehicle patients; only two of the five adequately demonstrated efficacy for fine facial wrinkling [1]. The fine-wrinkle distribution from the four studies in lightly pigmented subjects, 279 on tretinoin and 280 on vehicle, reads like this [1]:

• Worsened: 1% tretinoin vs 3% vehicle
• No change: 40% vs 58%
• Minimal improvement: 35% vs 27%
• Mild improvement: 15% vs 9%
• Moderate improvement: 10% vs 3%

Improvement was graded on a 10-unit scale, where minimal means a 1-unit reduction and moderate means a reduction of 3 units or more [1]. Add the top three categories and about 60% of tretinoin users had at least minimal improvement after 24 weeks, against about 39% of vehicle users (27% minimal, 9% mild, 3% moderate). Moderate improvement was reported in 10% of Renova users and 3% of vehicle users [1].

One caveat sits inside those numbers: every participant, vehicle included, used the same comprehensive skin care and sun avoidance program, which included sunscreen, protective clothing and non-prescription emollient creams, and the label notes that many vehicle patients achieved the desired palliative effect from that program alone [1].

The picture was different in the one single-center study of 107 darkly pigmented subjects with Fitzpatrick skin types IV to VI, where 29% of Renova users had minimal or mild improvement in fine wrinkling compared with 43% of vehicle users; the label notes that this may reflect the small size of the study [1].

The label also sets hard limits on what a response means. Renova does not eliminate wrinkles, repair sun-damaged skin, reverse photoaging or restore a more youthful skin structure, and it has not demonstrated a mitigating effect on coarse or deep wrinkling, tactile roughness, mottled hyperpigmentation, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia or dermal elastosis [1]. Renova 0.02% is indicated only as an adjunct for the mitigation of fine facial wrinkles; the label does not indicate it for acne [1].

What About Sun-Damaged Skin?

A 1991 multicenter study (Weinstein et al.) randomized 251 subjects with mild to moderate photodamaged facial skin to an emollient cream at 0.05% or 0.01% or to vehicle, double-blind, for 24 weeks [2]. Overall improvement was seen in 79% of subjects who received 0.05% tretinoin compared with 48% of vehicle-treated subjects, with significant reductions in fine wrinkling, mottled hyperpigmentation, roughness and laxity [2]. Histologic changes of increased epidermal thickness, decreased melanin content and stratum corneum compaction were reported alongside the clinical improvement, and erythema, peeling and stinging were usually mild and well tolerated [2].

That is a different formulation and strength from the 0.02% Renova cream. The Renova label states that its 0.02% cream has not demonstrated a mitigating effect on mottled hyperpigmentation, tactile roughness or skin laxity [1], while the 1991 study reported significant reductions in those measures with the 0.05% emollient cream [2].

Why Your Own Result May Not Match These Numbers

The measured window is 24 weeks. That is the treatment period in the Renova trials and in the 1991 photodamage study [1][2]. The Renova label also states that neither the safety nor the efficacy of daily use for more than 52 weeks has been established [1].

More product does not speed it up. The label states that application of larger amounts of medication than recommended has not been shown to lead to more rapid or better results, and that marked redness, peeling or discomfort may occur [1].

Some improvement may fade after stopping. The Renova label says patients may lose some of its mitigating effects after 12 weeks off treatment [1].

Local irritation was nearly universal. In vehicle-controlled studies involving 339 patients who applied Renova to the face, almost all reported one or more local reactions such as peeling, dry skin, burning, stinging, erythema and pruritus; 32% of study patients had skin irritation that was severe, led to temporary discontinuation or led to use of a mild topical corticosteroid, about 7% needed short-term mild topical corticosteroids against less than 1% of controls, and about 4% discontinued because of adverse reactions [1].

What Response Rates Have Been Reported for Other Uses?

Melasma. Two combined 8-week randomized, investigator-blind studies enrolled 641 adults with moderate to severe melasma. A triple-combination cream containing tretinoin 0.05%, hydroquinone 4% and fluocinolone acetonide 0.01% produced complete clearing in 26.1% of patients at week 8 versus 4.6% across the other treatment groups, and a 75% reduction in pigmentation in more than 70% versus 30% [3]. Those figures belong to the combination product, not to tretinoin used alone.

Vulvar lichen sclerosus (off-label). Seventeen patients used tretinoin 0.025% cream on alternate days for 24 weeks; 12 (70.6%) met the study response criteria, 35.3% reached at least a 75% improvement in subjective scores and 17.6% in objective scores, 6 patients (35.3%) had side effects that were mainly mild erythema and burning, and none discontinued because of side effects [4].

What the Label Says to Watch For

Photosensitivity is spelled out. The Renova label directs that exposure to sunlight, including sunlamps, be avoided or minimized because of heightened sunburn susceptibility, that sunscreens with a minimum SPF of 15 and protective clothing be used, that patients with sunburn not use the product until fully recovered, and that it not be used by people taking drugs known to be photosensitizers such as thiazides, tetracyclines, fluoroquinolones, phenothiazines or sulfonamides because of possible augmented phototoxicity [1]. It should be kept out of the eyes, mouth, angles of the nose and mucous membranes, and topical use may cause severe local erythema, pruritus, burning, stinging and peeling at the application site [1]. Medicated or abrasive soaps, cleansers and cosmetics with a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime may increase irritation [1].

The Renova label instructs that the product not be used by patients who are pregnant, attempting to become pregnant or at high risk of pregnancy, or who are sunburned or have eczema or other chronic skin conditions of the face [1]. Its pregnancy section describes 30 human cases of temporally associated congenital malformations reported over two decades with another topical tretinoin formulation, including five holoprosencephaly cases, with no definite pattern of teratogenicity and no causal association established, and notes that topical tretinoin in animal teratogenicity tests has generated equivocal results [1].

FDA-approved topical tretinoin is a prescription product. Compounded tretinoin is not FDA-approved, and FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed [5]. HealthRX.com offers tretinoin by prescription.